Global Antithrombotic Drug Market Drives China's Heparin Export
Business News Agency December 20th The rapid increase in global demand for antithrombotic drugs has led to an increase in the sales of heparin drugs. Heparin drugs are mainly used in cardio-cerebral vascular disease and hemodialysis treatment, and drug users focus on older and obese people. . Therefore, the main consumer markets for heparin drugs are concentrated in developed countries such as Europe, the United States, and Japan. In recent years, the demand for heparin drugs has been very strong in the international market. In 2009, the global market for heparin drugs reached US$6.577 billion. The average annual compound annual growth rate of 2006-2009 exceeded 10%, which is higher than the growth rate of the global pharmaceutical market. It is expected that by 2012, the global heparin drug market will reach US$9.102 billion.
According to statistics, in 2006, the total sales of heparin drugs was 4.915 billion U.S. dollars, which increased to 5.99 billion U.S. dollars in 2008. It is estimated that the sales volume will reach 9.102 billion U.S. dollars in 2012, and the compound annual growth rate is expected to be 11.03%.
In 2009, China's total export of heparin and its salt was 111.71 tons, an increase of 71.63% over the same period of last year; the export amount was 698 million US dollars, an increase of 208.77% year-on-year; the average export price was 6248.96 US dollars/kg, an increase of 79.91% year-on-year. Heparin and its salts are one of the few products that have risen in volume and price throughout the year in the global economic crisis.
In the first half of 2010, China’s total exports of heparin were 56.13 tons, an increase of 25.52% compared to the second half of 2009; the average export price was 10431.38 USD/kg, an increase of 124.59% year-on-year in 2009, an increase of 1.71% from the second half of 2009 The export volume reached US$586 million, an increase of 113.12% compared to the first half of 2009 and an increase of 27.66% compared to the second half of 2009.
The heparin products exported by China are mainly heparin APIs. Heparin APIs exported from China account for nearly 50% of the world's total. Heparin APIs are mainly used for the production of standard heparin preparations or low molecular weight heparin APIs, approximately three times of the world's total. One of the heparin APIs is used to make standard heparin preparations, and the remaining two-thirds are used as raw materials for the production of low molecular weight heparin APIs.
According to relevant statistics, in 2009, the global sales of heparin APIs was 29.71 trillion units, and the average annual compound growth rate from 2007 to 2009 was 12.92%. It is expected that the market size in 2013 will reach 40.81 trillion units.
At the same time, the standard heparin preparations in the international market have also achieved rapid growth in recent years. In 2006, the global market for heparin preparations was 305 million U.S. dollars. However, by 2009, the global market for heparin preparations reached 1.023 billion U.S. dollars. Dollars.
The demand for heparin in the world has also driven the development of the heparin pharmaceutical market in China. In recent years, emerging economies represented by China have developed rapidly, residents’ lifestyles have changed, medical standards have improved, and demand for heparin-based drugs has continued to grow. The country “sees the same line†and climbs year by year. In the past two years, the average annual compound growth rate of China’s heparin pharmaceutical market is 16.73%, which is higher than the global average.
According to statistics, in 2006, the total sales of heparin drugs was 4.915 billion U.S. dollars, which increased to 5.99 billion U.S. dollars in 2008. It is estimated that the sales volume will reach 9.102 billion U.S. dollars in 2012, and the compound annual growth rate is expected to be 11.03%.
In 2009, China's total export of heparin and its salt was 111.71 tons, an increase of 71.63% over the same period of last year; the export amount was 698 million US dollars, an increase of 208.77% year-on-year; the average export price was 6248.96 US dollars/kg, an increase of 79.91% year-on-year. Heparin and its salts are one of the few products that have risen in volume and price throughout the year in the global economic crisis.
In the first half of 2010, China’s total exports of heparin were 56.13 tons, an increase of 25.52% compared to the second half of 2009; the average export price was 10431.38 USD/kg, an increase of 124.59% year-on-year in 2009, an increase of 1.71% from the second half of 2009 The export volume reached US$586 million, an increase of 113.12% compared to the first half of 2009 and an increase of 27.66% compared to the second half of 2009.
The heparin products exported by China are mainly heparin APIs. Heparin APIs exported from China account for nearly 50% of the world's total. Heparin APIs are mainly used for the production of standard heparin preparations or low molecular weight heparin APIs, approximately three times of the world's total. One of the heparin APIs is used to make standard heparin preparations, and the remaining two-thirds are used as raw materials for the production of low molecular weight heparin APIs.
According to relevant statistics, in 2009, the global sales of heparin APIs was 29.71 trillion units, and the average annual compound growth rate from 2007 to 2009 was 12.92%. It is expected that the market size in 2013 will reach 40.81 trillion units.
At the same time, the standard heparin preparations in the international market have also achieved rapid growth in recent years. In 2006, the global market for heparin preparations was 305 million U.S. dollars. However, by 2009, the global market for heparin preparations reached 1.023 billion U.S. dollars. Dollars.
The demand for heparin in the world has also driven the development of the heparin pharmaceutical market in China. In recent years, emerging economies represented by China have developed rapidly, residents’ lifestyles have changed, medical standards have improved, and demand for heparin-based drugs has continued to grow. The country “sees the same line†and climbs year by year. In the past two years, the average annual compound growth rate of China’s heparin pharmaceutical market is 16.73%, which is higher than the global average.
Super Absorbent Bath Mat,Bath Mat,Diatomite Health Hot Bath Mat,Non Slip Bath Mat
Dongguan Vanilla Bioengineering Co., Ltd. , https://www.healthecigarette.de